Saturday 17 October 2026
Export KRMD’s income statement to Excel — free account
KORU Medical Systems, Inc.
KRMD Healthcare Medical Instruments & Supplies
KORU Medical Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.1 million, up 22.2% from fiscal 2024. In the quarter to June 2026, revenue grew 18.2%, EPS grew 222.2%, free cash flow grew 26.2% and total debt fell 50.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
3.00
0.03
−0.99%
Follow KRMD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.53 | 6.52 | 4.63 | 4.29 | |
P/FCF ratio |
0.00 | 0.00 | 1,645.82 | 775.14 | |
P/Operating CF |
2,707.87 | 245.11 | 13,625.60 | 895.66 | |
P/B ratio |
10.76 | 15.74 | 11.84 | 10.72 | |
Price to Tangible BV |
11.22 | 16.40 | 12.36 | 11.81 | |
EV/Sales |
4.32 | 6.31 | 4.43 | 4.11 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
549.31 | 561.32 | 268.09 | 133.24 | |
EV/FCF |
(992.05) | (532.53) | 1,574.16 | 742.24 | |
Quick Ratio |
1.78 | 1.88 | 1.70 | 2.00 | |
Current Ratio |
2.48 | 2.44 | 2.33 | 2.72 | |
Net Debt/EBITDA |
12.59 | 23.90 | 13.07 | (9.82) | |
Debt/Assets |
0.43% | 0.28% | 0.16% | 0.26% | |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.43 | 1.48 | 1.55 | 1.69 | |
Operating CF/Net income |
(0.08) | (2.25) | (0.02) | 0.86 | |
Capex/Depreciation |
(0.26) | (2.35) | (0.46) | (2.75) | |
Research and Development Expense of Revenue |
8.97% | 10.51% | 11.19% | 8.88% | |
Selling, General and Administrative Expense of Revenue |
57.63% | 55.44% | 55.95% | 49.31% | |
Intangible Assets out of Total Assets |
0.03 | 0.02 | 0.02 | 0.06 | |
Share Based Compensation of Revenue |
6.03% | 8.93% | 5.79% | 3.80% | |
Graham Net Nets |
0.05 | 0.03 | 0.04 | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.21%) | (1.11%) | (1.26%) | (1.06%) | |
Free Cash Flow Yield |
(0.10%) | (0.18%) | 0.06% | 0.13% | |
Revenue per Share |
0.23 | 0.24 | 0.25 | 0.26 | |
Operating CF per Share |
0.00 | 0.02 | 0.00 | 0.00 | |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.01) | |
Free Cash Flow per Share |
0.00 | 0.01 | 0.00 | (0.01) | |
Cash per Share |
0.18 | 0.19 | 0.19 | 0.18 | |
Shareholders Equity per Share |
0.36 | 0.37 | 0.37 | 0.39 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.36 | 0.37 | 0.37 | 0.39 | |
Free Cash Flow |
0.01 | 0.67 | (0.08) | (0.36) | |
Working Capital |
11.59 | 11.79 | 11.74 | 12.33 | |
Capital Expenditures |
(0.05) | (0.42) | (0.09) | (0.58) | |
Net Current Asset Value |
8.78 | 8.84 | 8.92 | 9.60 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.04 | 0.01 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.38 | 6.26 | 6.29 | 5.59 | |
Average Payables |
1.77 | 1.96 | 2.32 | 2.00 | |
Average Inventory |
4.17 | 3.24 | 3.88 | 4.23 | |
Average Assets |
27.25 | 27.71 | 27.90 | 26.74 | |
Average Common Equity |
17.10 | 16.93 | 16.63 | 17.29 |
Columns are period end dates